|
||
J. Exp. Med.,
Volume 187, Number 1, January 5, 1998 79-87
By

From the * Division of Developmental and Clinical Immunology, the Department of Medicine, the
Department of Pediatrics, and the Department of Microbiology, University of Alabama at Birmingham,
Birmingham, Alabama 35294; and the Type I interferons
Howard Hughes Medical Institute, Birmingham,
Alabama 35294
and
, naturally produced regulators of cell growth and differentiation,
have been shown to inhibit IL-7-induced growth and survival of B cell precursors in vitro. After confirming an inhibitory effect on B lymphopoiesis in an ex vivo assay, we treated newborn
mice with an active IFN-
2/
1 hybrid molecule to assess its potential for regulating B and T
cell development in vivo. Bone marrow and splenic cellularity was greatly reduced in the IFN-
2/
1-treated mice, and B lineage cells were reduced by >80%. The bone marrow progenitor
population of CD43+B220+HSA
cells was unaffected, but development of the CD19+ pro-B
cells and their B lineage progeny was severely impaired. Correspondingly, IL-7-responsive
cells in the bone marrow were virtually eliminated by the interferon treatment. Thymus cellularity was also reduced by >80% in the treated mice. Phenotypic analysis of the residual thymocytes
indicated that the inhibitory effect was exerted during the pro-T cell stage in differentiation. In IFN-
/
receptor
/
mice, T and B cell development were unaffected by the IFN-
2/
1 treatment. The data suggest that type I interferons can reversibly inhibit early T and B cell development by opposing the essential IL-7 response.
This article has been cited by other articles:
| TABLE OF CONTENTS |
|